• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Imprimis, Precision Lens sign marketing and sales agreement

April 18, 2017 By Sarah Faulkner

Imprimis Pharmaceuticals logoImprimis Pharmaceuticals (NSDQ:IMMY) said today that it signed a 3-year exclusive sales agreement with Precision Lens. According to the deal, Precision Lens plans to deploy a sales team to expand Imprimis’ ophthalmic portfolio in 13 states across the U.S. Midwest.

Precision Lens said it will sell San Diego-based Imprimis’ Dropless Therapy, LessDrops combination eye drops and other eye care products.

“With more than 60% IOL market share and a long track record of earning their customer’s respect through exceptional service, expertise and integrity, we could not want for a better partner to help us bring our innovative family of ophthalmic products to more physicians, large practice groups, surgery centers and hospitals,” Imprimis CEO Mark Baum said in prepared remarks. “We look forward to working with Precision Lens and believe this important relationship will increase sales productivity and strengthen our position in this important region of the country. Precision Lens will be a key partner as we introduce our Simple Drops glaucoma program in the 2nd quarter and our new dry eye program, expected to launch in the second half of the year. Precision Lens’ mission to offer eye care providers the best technology options available in the marketplace marries perfectly with the Imprimis commitment of providing patients with affordable access to innovative and high-quality medications.”

IMMY shares were trading at $3.87 today in mid-afternoon activity, up 2.1%.

“We are very selective about the companies we represent and believe the portfolio of innovative ophthalmic medications from Imprimis, including those made from its FDA-registered outsourcing facility, will be very well-received by our customers,” Precision Lens CEO Paul Ehlen added. “For over 27  years we have been successfully representing leading ophthalmology companies and providing healthcare professionals with a wide array of innovative solutions for the care of their patients. We are excited to deploy a dedicated team to exclusively promote Imprimis’ portfolio within our territory. Imprimis’ Dropless Therapy and LessDrops combination drops have the potential to become standard-of-care in the post-cataract surgery market. This, combined with the soon to be introduced preservative free glaucoma offerings and new dry eye medications, provide us with the value and innovation we strive to provide our customers.”

In October last year, Imprimis touted data from a peer-reviewed study of patients who received its Dropless therapy following cataract surgery.

The company uses a compounded antibiotic and steroid formulation in single, injectable doses administered by physicians following ocular surgery. The treatment is designed to eliminate the need for patient-administered eye drops, potentially eliminating patient non-compliance or dosing errors. The compounded formulations use Imprimis’ patent-pending SSP technology, which helps active pharmaceutical ingredients solubilize into a well-distributed particle suspension.

Filed Under: Featured, Optical/Ophthalmic, Wall Street Beat Tagged With: Imprimis Pharmaceuticals, precisionlens

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS